N

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707

Watchlist Manager
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Watchlist
Price: 14.82 CNY -0.74% Market Closed
Market Cap: 23.9B CNY
Have any thoughts about
Nanjing King-friend Biochemical Pharmaceutical Co Ltd?
Write Note

Relative Value

The Relative Value of one Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock under the Base Case scenario is 27.29 CNY. Compared to the current market price of 14.82 CNY, Nanjing King-friend Biochemical Pharmaceutical Co Ltd is Undervalued by 46%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
27.29 CNY
Undervaluation 46%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
66
vs Industry
24
Median 3Y
6.6
Median 5Y
7.5
Industry
2.6
Forward
5.4
vs History
vs Industry
23
Median 3Y
23.9
Median 5Y
26.9
Industry
23
Forward
27
vs History
42
vs Industry
33
Median 3Y
27.5
Median 5Y
13.8
Industry
17.8
vs History
52
vs Industry
28
Median 3Y
12
Median 5Y
12
Industry
25.4
vs History
69
vs Industry
24
Median 3Y
4.1
Median 5Y
5.4
Industry
2.2
vs History
68
vs Industry
23
Median 3Y
6.7
Median 5Y
8
Industry
2.8
Forward
5.6
vs History
44
vs Industry
15
Median 3Y
15.2
Median 5Y
15.3
Industry
5.4
vs History
vs Industry
19
Median 3Y
23.8
Median 5Y
26.4
Industry
13.7
Forward
17.8
vs History
vs Industry
23
Median 3Y
23.8
Median 5Y
26.4
Industry
17.2
Forward
11.8
vs History
42
vs Industry
33
Median 3Y
29.1
Median 5Y
14.1
Industry
16.5
vs History
34
vs Industry
23
Median 3Y
53.8
Median 5Y
18.9
Industry
19.3
vs History
69
vs Industry
29
Median 3Y
3.3
Median 5Y
4
Industry
2

Multiples Across Competitors

Competitors Multiples
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
23.9B CNY 6.4 -58.6 -56.5 -56.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.5B USD 18.5 90.4 48.6 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
364.1B USD 4.2 24.8 12 15.6
US
Merck & Co Inc
NYSE:MRK
248.4B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.5B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.2B CHF 4.2 12.6 10 14.9
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.5 169.4 253.8
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
CN
N
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Average P/E: 33.3
Negative Multiple: -58.6
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.8
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top